IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PCT/DO-EO

Commissioner for Patents Washington, DC 20231

"Express Mail" mailing label number EL 823 533 185 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 CFR § 1.10 on the date indicated above and addressed to: BOX PCT/DO-EO, Commissioner for Patents, Washington, DC 20231, on December 13, 2001.

NATIONAL STAGE APPLICATION TRANSMITTAL LETTER **APPLICATION FILING UNDER 35 U.S.C. § 371**

Transmitted herewith for filing is the patent application of:

Inventor(s)/Applicant(s):

Thonnard, Joelle

International Application No.:

PCT/EP00/05854

International Published Appln. No.: WO 01/00838

23 June 2000

International Filing Date:

25 June 1999

Priority Filing Dates: Thirty Month Date:

25 December 2001

Title:

"CLONING OF BASB110 ANTIGEN

FROM MORAXELLA (BRANHAMELLA)

CATARRHALIS"

1.	THIS	NEW .	APPLIC	ATION I	SA NAT	TIONAL S	TAGE	
<u>APPI</u>	LICAT	ION U	NDER P	CT, CHA	PTER I	<u>I</u> WITH A	REQUEST	ΓFOR
EXA	MINA'	TION V	WITHOU	UT DELA	Y TO T	HE UNIT	ED STATE	S
DESI	GNAT	ED/EL	ECTED	OFFICE	C (DO/EC	D/US).		

\boxtimes	This is a FIRST submiss	ion of item	s concerning	a filing under	35 U.S.C. §
	371;				
	mi: CDCOND		1		.: C1:

This is a SECOND or subsequent submission of items concerning a filing under 35 U.S.C. § 371.

This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).

A proper Demand for International Preliminary Examination was made by the 19TH 3. month from the earliest claimed priority date. Enclosed items are required for filing under 37 CFR § 1.53(b) and § 1.494(b) or § 1.495(b): One copy of International Publication No. WO 00/00838 冈 is transmitted herewith (required only if not transmitted by the (a) \boxtimes International Bureau) has been transmitted by the International Bureau (b) is not required, as the application was filed in the United States (c) Receiving Office (RO/US) **Fees** The basic national fee set forth in 37 CFR § 1.482 - International Preliminary \boxtimes Examination Fee not paid to USPTO but International Search Report prepared by the EPO or JPO - \$890.00 \boxtimes Claims in Excess of 20 (3 @ \$18.00) Independent Claims in Excess of 3 (@\$84.00) 5. Further enclosed are: One copy of International Preliminary Examination Report. \boxtimes 冈 One copy of International Search Report. One copy of Written Opinion. One copy of PCT Request as filed. One copy of Chapter II Demand as filed. A translation of the International Application into English (35 U.S.C. § 6. 371(c)(2)) Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. § 371(c)(3)) A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. § 371(c)(3)) 9. Still additional papers enclosed: Assignment with Assignment Recordation Form Cover Sheet Verification Statement Claiming Small Entity Status Declaration or oath is enclosed executed by the inventor An Information Disclosure Statement under 37 CFR § 1.97 and § 1.98 \boxtimes \boxtimes Return Acknowledgment Postcard

11.

10/18706 PATENT DOCKET NO. BM45394

10	Musle	eotide and/or Amino Acid Sequence Submission (ir applicable, all DEC 2001				
10.	Nucle	necessary)				
A.	Enclo	osed are:				
	(a)	Computer Readable Copy of the Sequence Listing				
	(b)	Paper Copy (identical to Computer Readable Copy) of the				
		Sequence Listing				
В.		Enclosed is a paper copy of the Sequence Listing. This paper copy and				
		a Computer Readable Form thereof are identical with the Computer				
		Readable Form in another application of the Applicant which is fully				
		identified as follows:				
		U.S. Application No.: @@				
		Filed: @@				
		Attorney Docket No.: @@				
		which is believed to comply with the rules set forth in 37 CFR § 1.821				
		et. seq. Applicants requests pursuant to 37 CFR § 1.821(e) that this				
		Computer Readable Form be used in the present application. Please				
		TRANSFER the sequence listing from the parent to this				
		application.				
C.	\boxtimes	Statement under 37 CFR § 1.821(f). The information recorded in				
		computer readable form is identical to the written Sequence				
		Listing.				
D.		Statement under 37 CFR § 1.821(g) (required when Sequence Listing				
		not submitted at the time of filing under 35 U.S.C. §111(a)) or 37 CFR				
		§1.821(f) (required when Sequence Listing not submitted at the time of				
		filing under the Patent Cooperation Treaty): The submission of the				
		Sequence Listing includes no new matter.				
E.		Amendment: Please enter the Sequence Listing into the application.				
<u>Prelir</u>	ninary	Amendment				
Prior	to calcu	ulation of fees, kindly enter:				
\boxtimes	Preliminary Amendment submitted herewith					
	do not enter Preliminary Amendment					

The correspondence address for this application is the customer No. provided below:

Insert Bar Code Label Here:



25308

13. Fee payment being made at this time is enclosed:

*	Basic filing fee (\$890.00)	890.00
*	Claims in Excess of 20 (3 @ \$18.00)	54.00
	Independent Claims in Excess of 3 (@\$84.00)	00.00

* Total Fees enclosed:

\$944.00

14. The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Account No. 50-0258. This letter is filed in duplicate for accounting purposes.

Respectfully submitted,

Teresa O. Bittenbender Registration No. 47,425 Attorney for Applicant

DECHERT 1717 Arch Street 4000 Bell Atlantic Tower Philadelphia, PA 19103

Fax: (215) 994-2222

Attn.: Teresa O. Bittenbender, Esq.

(215) 994-2213

123874.1.07